June 11-18, 2026, European Hematology Association (EHA) Congress

Phase 1 First-in-human study of AUR112, a highly selective MALT1 inhibitor, in relapsed lymphoid malignancies

April 17-22, 2026, American Association for Cancer Research

1) Exceptionally selective and orally bioavailable p300 degraders for the treatment of CBP-mutant and p300-dependent cancers 2) Discovery and characterization of once in a month intravenous and orally bioavailable SMARCA2 degraders for

April 13- 16, 2026, Drug Discovery Chemistry

1) Novel Macrocyclic KIF18A Inhibitors for Treatment of Chromosomally Unstable Tumors: Discovery and Preclinical Characterization   2) Discovery and Optimization of a First-in-Class p300-Selective Oral Degrader Candidate